Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. More Details
Flawless balance sheet with acceptable track record.
Share Price & News
How has Maxigen Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1783 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 1783's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of TW stocks.
7 Day Return
TW Personal Products
1 Year Return
TW Personal Products
Return vs Industry: 1783 exceeded the TW Personal Products industry which returned -15.1% over the past year.
Return vs Market: 1783 exceeded the TW Market which returned 36.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Maxigen Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StMaxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?
5 months ago | Simply Wall StWe Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings
Is Maxigen Biotech undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1783 (NT$54.8) is trading above our estimate of fair value (NT$54.57)
Significantly Below Fair Value: 1783 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1783 is poor value based on its PE Ratio (55.8x) compared to the TW Personal Products industry average (15x).
PE vs Market: 1783 is poor value based on its PE Ratio (55.8x) compared to the TW market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1783's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1783 is overvalued based on its PB Ratio (4.7x) compared to the TW Personal Products industry average (2x).
How is Maxigen Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Maxigen Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Maxigen Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1783 has a large one-off gain of NT$22.5M impacting its June 30 2021 financial results.
Growing Profit Margin: 1783's current net profit margins (16.1%) are higher than last year (12.8%).
Past Earnings Growth Analysis
Earnings Trend: 1783 has become profitable over the past 5 years, growing earnings by 47.8% per year.
Accelerating Growth: 1783's earnings growth over the past year (31.1%) is below its 5-year average (47.8% per year).
Earnings vs Industry: 1783 earnings growth over the past year (31.1%) exceeded the Personal Products industry 17.9%.
Return on Equity
High ROE: 1783's Return on Equity (8.4%) is considered low.
How is Maxigen Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: 1783's short term assets (NT$501.5M) exceed its short term liabilities (NT$104.4M).
Long Term Liabilities: 1783's short term assets (NT$501.5M) exceed its long term liabilities (NT$8.6M).
Debt to Equity History and Analysis
Debt Level: 1783 is debt free.
Reducing Debt: 1783 has no debt compared to 5 years ago when its debt to equity ratio was 35.4%.
Debt Coverage: 1783 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1783 has no debt, therefore coverage of interest payments is not a concern.
What is Maxigen Biotech current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1783's dividend (1.48%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (1.93%).
High Dividend: 1783's dividend (1.48%) is low compared to the top 25% of dividend payers in the TW market (5.25%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 1783 has been paying a dividend for less than 10 years.
Growing Dividend: 1783's dividend payments have increased, but the company has only paid a dividend for 3 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (74.4%), 1783's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Sung-Ching Chen, Ph D, serves as President at Maxigen Biotech Inc. and served as its Director since 2020 until July 2021. He serves as Vice President of Biomedical at Maxigen Biotech Inc. Dr. Chen join...
Experienced Board: 1783's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.8%.
Maxigen Biotech Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Maxigen Biotech Inc.
- Ticker: 1783
- Exchange: TWSE
- Founded: 1998
- Industry: Personal Products
- Sector: Household
- Market Cap: NT$4.220b
- Shares outstanding: 77.00m
- Website: https://www.mbi.com.tw
- Maxigen Biotech Inc.
- No. 88, Keji 1st Road
- Guishan District
- Taoyuan City
Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. The company offers Formagraft, a bone graft substitute; Formas...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 15:19|
|End of Day Share Price||2021/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.